Transitioning from R&D to Pre-Clinical Development
So you’ve completed the proof-of-concept studies, and the data is in. Congratulations, your start-up is ready for the next major phase in the commercialization journey: pre-clinical development. This pivotal step in a biotech’s progression demands careful planning as the requirements and necessary expertise of the company are changing and expanding beyond what was needed during the initial development of your asset.
During this transition, the organization shifts from skill sets needed for discovery (such as proof-of-concept studies and early-stage development) to specialized knowledge and proficiency in managing compliance, understanding regulatory standards, creating reproducible studies and preparing documentation for regulatory submission.
At this in-person event, listen to lessons learned from experts and founders who have successfully gone through this phase of development and how to prepare for this critical milestone. Enjoy networking, heavy appetizers and refreshments after the panel.
Agenda
4:00PM Registration
4:30PM Panel Discussion
5:30PM Networking with refreshments and heavy appetizers
Speakers
- Stephen M. Perry, Founder & CEO, Kymanox
- Phillip Kim, PhD, MBA, President and CEO, Trutino BioSciences
- Nancy Hong, PhD, Venture Capital Investor
- Danielle Bogdanowicz, PhD, VP Business Ops and Strategy, BioLabs (Moderator)
Registration
Please enter your Name, Title, and Company EXACTLY as you would like it to appear on your nametag, as we use this information as is when printing. Thank you!